Announced details
Fracture treatment and implant products
Purity of at least 99.95%. The period over which the material dissolves and is absorbed in the body can be controlled.
Patent holders (NITTOSEIKO CO.,LTD. and 4 others)
Patent No. 122078; patent registration date: 22 June 2026; expiration date: Not disclosed
The impact on results for the fiscal year ending December 2026 is expected to be minor. The company believes the patent will contribute to improved results over the medium to long term.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Medical-grade, bioabsorbable high-purity magnesium material; biodegradable medical devices (BIODEGRADABLE MEDICAL IMPLEMENT) |
| Relationship with the Company | Patent holders (NITTOSEIKO CO.,LTD. and 4 others) |
| Applicable area | Fracture treatment and implant products |
| Registration number and expiry date | Patent No. 122078; patent registration date: 22 June 2026; expiration date: Not disclosed |
| Quantitative Effects | Purity of at least 99.95%. The period over which the material dissolves and is absorbed in the body can be controlled. |
| Impact on Business Performance | The impact on results for the fiscal year ending December 2026 is expected to be minor. The company believes the patent will contribute to improved results over the medium to long term. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company is advancing the application and development of implant products made from pure magnesium with a purity of at least 99.95%, offering excellent biocompatibility and biosafety. It stated that the exclusive use of the technology in the ASEAN market is expected to contribute to future business expansion.